Physician profile
Shiva Poola
NPI 1437543642
$2,842.91
in general payments reported to CMS, 2019-2025
20 companies · $912 in 2025
The $912 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $165 · 2022: $211 · 2023: $287 · 2024: $1,268 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624 · Travel and Lodging: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.57 |
| Travel and Lodging | $843.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,315.41 | 2024-2025 | Exalt Model D, General - Biliary Devices, Axios |
| Abbvie INC. | $465.01 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $220.52 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Merck Sharp & Dohme LLC | $121.24 | 2021-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $88.05 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $82.49 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $78.58 | 2021-2023 | Ocaliva |
| Janssen Biotech, INC. | $74.87 | 2024-2025 | Tremfya, Stelara |
| Aimmune Therapeutics, INC. | $72.24 | 2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $65.34 | 2025 | Dupixent |
| Gilead Sciences, INC. | $56.18 | 2025 | |
| Janssen Scientific Affairs, LLC | $36.63 | 2024 | |
| Genzyme Corporation | $30.99 | 2025 | |
| Pfizer INC. | $29.70 | 2025 | |
| Nestle Healthcare Nutrition INC. | $21.87 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.69 | 2025 | Omvoh |
| Vivus LLC | $17.99 | 2025 | Pancreaze |
| Olympus America INC. | $16.95 | 2023 | Evis Exera III Duodenovideoscope |
| Ardelyx, INC. | $14.55 | 2025 | Ibsrela |
| Qol Medical, LLC | $13.61 | 2025 | Sucraid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiva Poola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.